Thrombopoietin Receptor Agonist Patient experience survey
- Conditions
- Immune Thrombocytopenia
- Registration Number
- NL-OMON22426
- Lead Sponsor
- Sobi
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Not specified
- Target Recruitment
- 150
A subject must fulfill the following criteria in order to be included in the study:
1.Men or women =18 years of age
2.Formal diagnosis of primary ITP according to the ASH and ICR guidelines [14, 25]
3.Currently or have previously received a TPO-RA (either eltrombopag and/or romiplostim) in the last 12 months
4.Have been treated with a TPO-RA for a minimum of 3 months, with at least some of the treatment received in the last 12 months
5.Provide written informed consent
6.Ability to understand and respond in English; this does not need to be the participants’ first language or even their own language if they wish to use their own translator. If recruitment appears to be limited by this, then translations of the survey will be made. Further plans for deployment will also see the survey translated into Dutch, French, German, Italian and Spanish
The presence of any of the following will exclude a subject from inclusion in the study:
1.Known secondary immune thrombocytopenia
2.Foreseeable inability to cooperate with given instructions or study procedures
3. Inability to give consent
Study & Design
- Study Type
- Observational non invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The relative preferences towards TPO-RA product characteristics
- Secondary Outcome Measures
Name Time Method Disease characteristics, patterns of treatment and satisfaction with therapy